Regulatory
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3
MRNA
FY2025 Q4
개선
Moderna, Inc. 실적 발표
Buzzberg 분석
FDA refusal to file on flu vaccine creates uncertainty
Moderna's FY2025 Q4 call highlighted a return to revenue growth in 2026 driven by international partnerships and the successful launch of Mnext Spike, while managing costs. The company faced regulatory headwinds in the US for its flu vaccine but is progressing internationally. Key pipeline catalysts include INT oncology data and norovirus readouts in 2026. FY2025 revenue was $1.9B with a net loss of $2.8B; cash and investments ended at $8.1B.
Buzzberg 분석 FDA refusal to file on flu vaccine creates uncertainty Moderna's FY2025 Q4 call highlighted a return to revenue growth in 2026 driven by international partnerships and the successful launch of Mnext Spike, while managing costs. The company faced regulatory headwinds in the US for its flu vaccine but is progressing internationally. Key pipeline catalysts include INT oncology data and norovirus readouts in 2026. FY2025 revenue was $1.9B with a net loss of $2.8B; cash and investments ended at $8.1B. 전체 분석 보기분석 접기
Moderna's FY2025 Q4 call highlighted a return to revenue growth in 2026 driven by international partnerships and the successful launch of Mnext Spike, while managing costs. The company faced regulatory headwinds in the US for its flu vaccine but is progressing internationally. Key pipeline catalysts include INT oncology data and norovirus readouts in 2026. FY2025 revenue was $1.9B with a net loss of $2.8B; cash and investments ended at $8.1B.
- 2026 guidance: up to 10% revenue growth, R&D spend ~$3B, SG&A ~$1B, capex $200-300M, ending cash $5.5-6B.
- Mnext Spike captured 24% US retail market share in 2025 and is a key 2026 growth driver.
- International growth driven by multi-year agreements with UK ($200M order in H1 2026), Canada, Australia, Mexico, Taiwan, and Brazil.
매출$0.678B보고값
주당순이익(EPS)$-2.11보고값
매출총이익률33.33%보고값
잉여현금흐름$0.912B보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Guidance
Expects 2026 revenue growth of up to 10%
Pipeline
Antismerin phase 3 adjuvant melanoma data expected this year
핵심 내용 3개 더 보기
Pipeline
Norovirus phase 3 data expected in 2026
Commercial
Mnex Spike captured 24% US retail market share in launch year
Costs
2026 cash costs guided to $4.2 billion
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $0.678B | 보고값 |
| 주당순이익(EPS) | $-2.11 | 보고값 |
| 매출총이익률 | 33.33% | 보고값 |
| 잉여현금흐름 | $0.912B | 보고값 |
| 자본지출 | $0.039B | 보고값 |
| 순이익 | $-0.826B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | $0.2B–$0.3B | $0.25B | 신규 제시 |
| 잉여현금흐름 | FY2026 | $5.5B–$6B | $5.75B | 신규 제시 |
| 영업이익률 | FY2026 | $4.9B | $4.9B | 신규 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Measured
Management acknowledged regulatory setbacks but emphasized progress, cost discipline, and multiple growth drivers, striking a balanced and forward-looking tone.
투자 및 생산능력
Management guided 2026 capital expenditures to $200-300 million, including investment in building fill-finish capacity in Norwood, Massachusetts.
아래에 언급된 기업 6개 모두 표시
기업발표 이후 수익률
고객
고객
Stéphane Boncel
Mexico is a committed multi-year customer for Moderna's respiratory vaccines, providing demand visibility and international revenue growth.
근거
“We also announced earlier this week a five-year strategic agreement with the government of Mexico for respiratory vaccine supply.”
파트너
파트너
Stéphane Boncel
Merck is the co-developer and commercial partner for Moderna's lead individualized cancer therapy (INT). Management's confidence is reinforced by positive five-year data, implying progress toward a potential BLA submission by Merck.
근거
“For intramural or individual cancer therapy developed in partnership with Merck, we recently reported positive five-year phase two data in adjuvant melanoma.”
파트너
Stéphane Boncel
Recordati gains global commercialization rights for Moderna's PA candidate, leveraging its rare disease infrastructure; for Recordati, this is a potential new late-stage asset in its portfolio.
근거
“First, an agreement with Ricardati for the global commercialization of our proprionic acidemia rare disease candidate, currently in a pivotal study.”
공급망
공급망
Stephen Hogue
Moderna's flu vaccine (mRNA-1010) was refused filing by the FDA, but is progressing in Europe, Canada, and Australia. The company highlights a potential strain mismatch in the US vs. Northern Hemisphere, positioning its mRNA platform as a solution for better strain matching. — If Moderna secures approvals abroad, it could gain share in international markets while incumbents like Pfizer and GSK are locked into traditional strain selection, leading to a competitive advantage in vaccine efficacy.
근거
“In the United States, it is a different strain than is circulating in the rest of the Northern Hemisphere. And there doesn't look like there would be great cross protection.”
공급망
Stéphane Boncel
The European respiratory vaccine market (approx. $1.8 billion) is opening up to Moderna in 2027, as a competitor's pandemic contract expires, allowing Moderna to launch multiple products and challenge incumbent players. — This opens a major new market for Moderna, directly competing with established players like Pfizer, GSK, and Sanofi, potentially disrupting their respiratory franchise revenues.
근거
“We look forward to significant expansion of our addressable market with the opening of the $1.8 billion European respiratory vaccines market. As a reminder, we have been excluded from this region for several years due to a competitor”
외부 신호
공급망 알파 · 3발표 이후 수익률
Moderna's flu vaccine (mRNA-1010) was refused filing by the FDA, but is progressing in Europe, Canada, and Australia. The company highlights a potential strain mismatch in the US vs. Northern Hemisphere, positioning its mRNA platform as a solution for better strain matching.
Moderna's COVID vaccine, Mnext Spike, captured 24% of the US retail market in its first season, with 34% among seniors, indicating rapid share gains against Pfizer's Comirnaty.
근거
“MNext Bike capturing 24% of the total U.S. retail market and 34% of the retail market among adults age 65 and older.”
The European respiratory vaccine market (approx. $1.8 billion) is opening up to Moderna in 2027, as a competitor's pandemic contract expires, allowing Moderna to launch multiple products and challenge incumbent players.
근거
“We look forward to significant expansion of our addressable market with the opening of the $1.8 billion European respiratory vaccines market. As a reminder, we have been excluded from this region for several years due to a competitor pande…”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 6개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.